Novel Drug Combination Shows Promise for Advanced HER2-Negat

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investiga

Related Keywords

Ireland , United States , Miami , Florida , California , New York , American , Michelle Rudek , Avonne Oconnor , Sarah Shin , Robert Anders , Roisin Connolly , Chenguang Wang , Johns Hopkins , Evanthia Roussos Torres , James Leatherman , Qingfeng Zhu , Alexei Hernandez , Los Angeles , Elizabeth Jaffee , Roussos Torres , Ludmila Danilova , Christine Rafie , Elana Fertig , Vered Stearns , Elizabeth Engle , Joseph Tandurella , Parker Institute , University Of Pittsburgh Cancer Institute , University College Cork , Cancer Therapy Evaluation Program , Kimmel Cancer Center , Ohio State University , Yale Cancer Center , University Of Miami Miller School Medicine , Johns Hopkins Kimmel Cancer Center , Johns Hopkins University School Of Medicine , University Of Pittsburgh Hillman Cancer Center , Genentech , Johns Hopkins University , National Cancer Institute , Home Group , Johns Hopkins Kimmel Cancer , Nature Cancer , Southern California Keck School , Johns Hopkins University School , Weill Cornell Medicine , Melinda Downs , Avonneo Connor , Miami Miller School , Pittsburgh Cancer Institute , Hillman Cancer Center , Cedars Sinai Cancer , Ohio State , Medical Home Group , Break Through Cancer ,